Gainers & Losers Of May 31: NDRM, CBIO, SUPN, MACK, VSTM...

(RTTNews) - The following are some of the biotech stocks that made their way onto the Day's Gainers & Losers' list of May 31, 2017.

GAINERS

1. NeuroDerm Ltd. (NDRM)

Gained 17.78% to close Wednesday's (May 31) trading at $23.85.

News: No news

Recent event:

On March 1, 2017, the Company reported positive results from its phase II trial of ND0612H for advanced Parkinson's disease.

Upcoming event:

The Company's CEO Oded S. Lieberman will make a corporate presentation at the Jefferies Global Healthcare Conference on June 7, 2017.

2. Catalyst Biosciences Inc. (CBIO)

Gained 13.43% to close Wednesday's trading at $4.73.

News: The European Medicines Agency Committee for Orphan Medicinal Products has issued a positive opinion recommending orphan drug designation for CB 2679d/ISU304 for the treatment of hemophilia B.

Catalyst Bio's South Korean collaborator, ISU Abxis, plans to initiate a Phase 1/2 proof-of-concept study of CB 2679d in individuals with severe hemophilia B in June 2017 in South Korea.

3. Supernus Pharmaceuticals Inc. (SUPN)

Gained 6.21% to close Wednesday's trading at $37.60.

News: No news

Near-term catalysts:

-- Two phase III trials for SPN-810, currently in development for Impulsive Aggression in patients aged 6 to 12 years who have ADHD, are underway. Enrollment in the trials is expected to continue through 2017.

-- A phase III trial of SPN-812, currently in development for patients aged 6 to 12 years with ADHD, is expected to be initiated during the second half of 2017. The Company is on track to meet with the FDA in the second quarter of 2017 for an end-of-Phase II meeting.

4. Flex Pharma Inc. (FLKS)

Gained 6.04% to close Wednesday's trading at $3.51.

News: No news

Upcoming events:

The Company will make presentations at

• The Jefferies Global Healthcare Conference on June 6, 2017 at 2:30 pm ET in New York, NY; • The JMP Securities Life Science Conference on June 20, 2017 at 2:00 pm ET in New York, NY.

LOSERS

1. Merrimack Pharmaceuticals Inc. (MACK)

Lost 23.26% to close Wednesday's trading at $1.82.

News: This is the fourth straight loss for the stock ever since the Company announced management changes on May 25, 2017.

Yasir Al-Wakeel will resign as the Company's Chief Financial Officer and Head of Corporate Development, effective June 9, 2017 to pursue other business interests.

2. Verastem Inc. (VSTM)

Lost 11.97% to close Wednesday's trading at $2.06.

News: No news

Near-term catalyst:

The Company's lead drug candidate is Duvelisib.

- Top-line data from its phase III study of Duvelisib in patients with relapsed or refractory Chronic Lymphocytic Leukemia, dubbed DUO, are expected in mid-year 2017.

Upcoming event:

The Company will make a presentation at the Jefferies 2017 Global Healthcare Conference on Friday, June 9 at 11:00 a.m. ET at the Grand Hyatt in New York City.

3. Zafgen Inc. (ZFGN)

Lost 7.38% to close Wednesday's trading at $3.39.

News: No news

Anticipated event:

A phase II clinical trial of ZGN-1061 in patients with type 2 diabetes who are overweight or obese is planned for initiation in the second half of this year.

4. Jounce Therapeutics Inc. (JNCE)

Lost 6.90% to close Wednesday's trading at $20.25.

News: No news

Recent events:

-- The Company made its debut on the NASDAQ Global Select Market on January 27, 2017, offering its shares at a price of $16.00 each.

-- The Company commenced enrollment in phase II portion of its Phase 1/2 study of JTX-2011 in patients with solid tumors on April 20, 2017. The Phase 1/2 study of JTX-2011 is known as ICONIC study.

Near-term catalyst:

-- Preliminary efficacy data from the ICONIC study is expected to be disclosed in the second half of 2017.